X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs PANACEA BIOTECH - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB PANACEA BIOTECH DR. REDDYS LAB/
PANACEA BIOTECH
 
P/E (TTM) x 29.1 176.1 16.5% View Chart
P/BV x 2.9 3.9 72.9% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 DR. REDDYS LAB   PANACEA BIOTECH
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
PANACEA BIOTECH
Mar-14
DR. REDDYS LAB/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs3,397149 2,284.3%   
Low Rs2,56082 3,110.6%   
Sales per share (Unadj.) Rs856.584.1 1,018.0%  
Earnings per share (Unadj.) Rs78.0-18.3 -425.8%  
Cash flow per share (Unadj.) Rs139.9-6.7 -2,088.4%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs739.883.7 883.8%  
Shares outstanding (eoy) m165.7461.25 270.6%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.51.4 253.3%   
Avg P/E ratio x38.2-6.3 -605.5%  
P/CF ratio (eoy) x21.3-17.2 -123.5%  
Price / Book Value ratio x4.01.4 291.8%  
Dividend payout %25.70-   
Avg Mkt Cap Rs m493,6327,074 6,977.7%   
No. of employees `00022.72.8 824.8%   
Total wages/salary Rs m31,0681,449 2,143.8%   
Avg. sales/employee Rs Th6,259.01,874.1 334.0%   
Avg. wages/employee Rs Th1,369.8527.0 259.9%   
Avg. net profit/employee Rs Th569.7-407.7 -139.7%   
INCOME DATA
Net Sales Rs m141,9615,154 2,754.5%  
Other income Rs m1,715100 1,718.4%   
Total revenues Rs m143,6765,254 2,734.9%   
Gross profit Rs m24,722-766 -3,226.2%  
Depreciation Rs m10,266711 1,443.9%   
Interest Rs m6341,503 42.2%   
Profit before tax Rs m15,537-2,881 -539.4%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m349-6 -6,122.8%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m2,96517 17,648.8%   
Profit after tax Rs m12,921-1,121 -1,152.3%  
Gross profit margin %17.4-14.9 -117.1%  
Effective tax rate %19.1-0.6 -3,272.0%   
Net profit margin %9.1-21.8 -41.8%  
BALANCE SHEET DATA
Current assets Rs m96,8373,810 2,541.5%   
Current liabilities Rs m84,1998,365 1,006.5%   
Net working cap to sales %8.9-88.4 -10.1%  
Current ratio x1.20.5 252.5%  
Inventory Days Days73156 47.1%  
Debtors Days Days9867 145.3%  
Net fixed assets Rs m102,55214,480 708.2%   
Share capital Rs m82961 1,352.4%   
"Free" reserves Rs m121,792903 13,486.0%   
Net worth Rs m122,6215,127 2,391.6%   
Long term debt Rs m5,4495,832 93.4%   
Total assets Rs m218,16519,433 1,122.6%  
Interest coverage x25.5-0.9 -2,783.0%   
Debt to equity ratio x01.1 3.9%  
Sales to assets ratio x0.70.3 245.4%   
Return on assets %6.22.0 316.3%  
Return on equity %10.5-21.9 -48.2%  
Return on capital %12.93.6 354.7%  
Exports to sales %54.624.5 222.7%   
Imports to sales %9.410.2 91.8%   
Exports (fob) Rs m77,5201,264 6,133.9%   
Imports (cif) Rs m13,274525 2,529.3%   
Fx inflow Rs m81,6701,539 5,306.0%   
Fx outflow Rs m26,355942 2,797.8%   
Net fx Rs m55,315597 9,262.4%   
CASH FLOW
From Operations Rs m21,444599 3,578.8%  
From Investments Rs m-18,404-438 4,202.8%  
From Financial Activity Rs m-3,692-303 1,220.1%  
Net Cashflow Rs m-1,144-141 809.6%  

Share Holding

Indian Promoters % 25.5 74.5 34.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 0.6 900.0%  
FIIs % 35.3 1.3 2,715.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 23.6 64.8%  
Shareholders   75,885 10,259 739.7%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   PLETHICO PHARMA  DIVIS LABORATORIES  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; PSU & Energy Stocks Decline(01:30 pm)

Indian share markets continued to trade in red during the noon session weak Asian markets. PSU stocks and energy stocks are witnessing majority of the selling activity.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Feb 22, 2018 01:55 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS